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Abstract     Hepatitis C virus (HCV) represents a fundamental issue for public health, with long term 
evolution and the gradual appearance of several complications and associated pathologies. One of 
these pathologies is represented by cryoglobulinemic vasculitis, a disorder characterized by the 
appearance in the patient’s serum of the cryoglobulins, which typically precipitate at temperatures 
below normal body temperature (37°C) and dissolve again if the serum is heated. Here, we 
describe the case of a patient diagnosed with HCV that, during the evolution of the hepatic 
disease, developed a form of cryoglobulinemic vasculitis.  
     The connection between the vasculitis and the hepatic disorder was revealed following 
treatment with interferon, with the temporary remission of both pathologies and subsequent 
relapse at the end of the 12 months of treatment, the patient becoming a non-responder. The 
particularity of the case is represented by both the severity of the vasculitic disease from its onset 
and the deterioration of renal function up to the predialitic phase, a situation not typical of the 
evolution of cryoglobulinemia. Taking into account the hepatic disorder, the inevitable evolution 
towards cirrhosis, and the risk of developing the hepatocellular carcinoma, close monitoring is 
necessary.      
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Highlights 
 
✓ This case reveals the close connection between the infection with the HCV and the 
cryoglobulinemic vasculitis 
✓ The particularity is represented by both the existence from the outset of the vasculitic 
disease and the current predialitic stage of the patient    
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Introduction 
Patients with chronic hepatitis C virus (HCV) 
infection are at risk for a variety of extrahepatic 
manifestations (EHMs). Based on large cohort studies, 
up to 70% of patients develop hepatitis C virus 
extrahepatic manifestations (1,2). Cryoglobulinemia 
represents a pathology based on the presence in the 
serum of immunoglobulins (Ig) that precipitate when 
the body temperature is lower than 37°C, becoming 
soluble again when the body temperature exceeds 37°C 
(3). The presence of the cryoglobulins in the serum 
determines the development of a syndrome of systemic 
inflammation that mainly affects the kidneys and the 
skin.  
According to the Brouet (4) classification, there are 
three types of cryoglobulinemias. 
• Type I, or the simple form (10-15%), is 
characterized by the presence of a monoclonal Ig (IgM 
isotype) in most of cases. It is usually asymptomatic and 
is present within the lympho-plasmocitary proliferation 
(Waldenström's macroglobulinemia, chronic lymphatic 
leukemia, multiple myeloma); 
• Type II, or the mixed form (50-60%), is made up of 
a monoclonal IgM component that acts as a rheumatoid 
factor (RF) and as an antibody against a second 
component, a polyclonal IgG isotype component. 
Although the second type of cryoglobulinemia has been 
considered to be a self-existing pathology (5-6), recent 
studies indicate its association with HCV in a proportion 
of 40-100, according to the geographical area (7-9). 
• Type III is also a mixed form, with immune 
complexes made up of two polyclonal Ig (10). The 
diagnosis of the mixed cryoglobulinemia syndrome is 
based on serologic, pathologic, and clinical criteria. 
 
Case Report 
 Patient A.A., 59 years old city dweller, was 
diagnosed in 2014 with HCV, after the performance of 
anti-HCV antibodies. In 2014, the patient underwent 
detailed investigations and renal biopsy due to the 
increase in liver disease symptomatology and the 
occurrence of systemic arterial hypertension, 
macroscopic hematuria, leg edemas, and Raynaud 
phenomena, being thus diagnosed with renal (chronic 
glomerulonephritis), cutaneous, and neurological 
cryoglobulinemic vasculitis. In 2015 she was 
administered a treatment with Interferon and Ribavirin 
for 12 months without a sustained virologic response. 
The patient had been diagnosed for several years with 
anemia by mixed and renal mechanism and iron-
deficiency anaemia; for this she has been administered 
iron-based medicines and Neorecormon (therapeutically 
corrected).  
 
Figure 1.  Livedo reticularis hyperpigmentary 
lesions at the level of the inferior extremities. 
The physical examination revealed the following 
aspects: a moderate sclero-tegumentary pallor, with the 
presence of certain livedo reticularis hyperpigmentary 
lesions and of purpuric lesions around the bilateral leg 
surface, gums bleeding, sicca phenomena (xerostomia, 
xerophtalmia), respiratory apparatus under normal 
limits, arterial tension reaching 140/80 mmHg and the 
pulse amounting to 80 beats per minute, the abdomen 
sensitive to palpation in the right hypochondrium, the 
liver with increased consistency, macroscopic 
hematuria, acro-paresthesia. 
The paraclinical investigation revealed the 
following: thrombocytes 120.000/mm3, erythrocyte 
sedimentation rate (ESR) 90 mm/1h, 130 mm/2h, serum 
urea 120 mg/dL, creatinine 3.6 mg/dL, eGFR 
13mL/min/1.73m2, proteinuria 800.0mg/24h, the Addis 
test 2580 erythrocytes/min, aspartataminotranspherasis 
(ASAT) 70U/L, alaninaminotranspherasis (ALAT) 
59U/L, alkaline phosphatase 67 U/L, gamma-glutamyl-
transpeptidase (GGT) 162 U/L, total bilirubin 0.48 
mg/dL, direct bilirubin 0.15 mg/dL, indirect bilirubin 
0.33 mg/dL, cholesterol 170 mg/dL, total protein 6.4 
g%, fibrinogen 458 mg/dL, C-reactive protein (CRP) 
1.74 mg/L, complement factors such as C3 109.96 
mg/dL (n: 90-180 mg/dL), IgA 183.96 mg/dL (n: 70-
400 mg/dL), IgG 1631.6 mg/dL (n: 700-1600 mg/dL), 
IgM 246 mg/dL (n: 40-230 mg/dL); the electrophoresis 
of the seric proteins: total protein 6.4 g%, 
albumin/globulin 1.25, serum albumin 55.6%, alpha-1 
globulin 2.2%, alpha-2 globulin 11.8%, beta-1 globulin 
6.2%, beta-2 globulin 3.3%, gama globulin 20.9% with 
the tendency to the monoclonal band in the gama 
mobility area. 
From the abdominal ultrasound we detected a liver 
with homogeneous echostructure, with several 
infracentimetric calcifications, hepatic left lobe reaching 
6.5 cm, hepatic right lobe reaching 15.5 cm, the vena 
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porta 8 mm, permeable, hepatopetal flow, both kidneys 
reduced in volume (9 cm), normal pancreas and spleen, 
normal values of the inferior vena cava, adenopathy 
reaching 1.1 cm, situated in the celiac trunk, with no 
peritoneal fluid. 
Taking into account the long-term evolution of 
hepatic disease, a superior digestive endoscopy was 
carried out. The endoscopy revealed a stomach with 
diffuse hyperemia of the mucous membrane and several 
petechiae at the level of the gastric body and bulb with 
diffuse hyperemia and several petechiae, without any 
esophageal varicose veins, or portal hypertensive 
gastropathy.  
For a better evaluation of the hepatic status, a real 
time sonoelastography (RTE) was carried out, that 
emphasized a tessellated structure with the 
predominance of the blue areas and a liver fibrosis 
index (LFI) of 2.18. 
 
 
Figure 2. RTE reveals the predominance of the 
blue areas and a LFI of 2.18 
 
Discussion 
Cryoglobulinemia induces a systemic vasculitis that 
mainly affects the small blood vessels and, to a smaller 
extent the medium arteries and veins, through the 
gradual build-up of circulating immune complexes and 
the activation of the complement cascade (9). It often 
coexists with the HCV infection, being cited as the main 
cause of type II mixed cryoglobulinemia (9). Anti-HCV 
antibodies are present, together with an active viral 
replication, in most patients with mixed 
cryoglobulinemia, the cryoprecipitates containing 
monoclonal IgM, rheumatoid molecules that mainly act 
against the antigen-antibodies immune complexes (7, 8, 
11, 12). 
Cryoglobulinemia manifests at the systemic level, 
affecting the skin, the kidneys, and the nervous system, 
with the severity of the disease varying case by case. 
Treatment can act either on the viral infection, resorting 
in this case to the therapy with interferon, or on 
thessymptoms, when treatment is based on 
corticotherapy, immunosuppressors, or plasmapheresis 
(12). 
The primary goal of treatment is HCV eradication, 
which is associated with improvement of clinical 
symptoms, especially in patients with mixed 
cryoglobulinemia (13-16). In patients with severe 
symptoms of mixed cryoglobulinemia, treatment with 
rituximab may be considered (17). Recent studies have 
also tested the combination of PEG-IFN/RBV and 
rituximab. The clinical response may be achieved faster 
and SVR is not diminished in patients who receive 
rituximab (18, 19). Triple therapy was effective in terms 
of virologic response as well as clinical response, but 
adverse events were frequent (>80% anemia, >50% 
infections) (20). Since 2015, IFN-free therapies have 
been an option for this group of patients, but so far data 
are limited. Recent data show that the INF-free 
combination of SOF/ RBV is highly effective in 
inducing clinical remission in patients with 
cryoglobulinemia vasculitis (78% after 24 weeks of 
treatment) in a cohort of 18 patients (21). 
Clinical remission was achieved in 50-70% of 
patients receiving IFN α plus RBV and was correlated 
with a significant reduction of viral concentrations (22). 
Despite successful antiviral treatment, cryoglobulinemic 
vasculitis may persist in a small collective (23). Recent 
data have demonstrated that rituximab is an effective 
and safe treatment for advanced liver disease with 
mixed cryoglobulinemia (24). Thus, the combination of 
rituximab with PEG-IFN α and ribavirin represents a 
therapeutic approach for patients with severe vasculitis 
from mixed cryoglobulinemia and resistant to antiviral 
therapy alone (25).  
With its recent introduction, the new interferon-free 
treatment consists of direct acting antivirals (DAA), 
although the role of rituximab remains to be observed, 
as non-response is unusual. The efficacy and safety of 
treatment with sofosbuvir in HCV-induced MC have 
had an SVR12 rate of 83% and has been associated with 
eGFR improvement as well as a reduction in proteinuria 
(26).  
Renal impairment has been observed as an adverse 
event associated with the use of telaprevir and 
boceprevir (27). In patients with severe renal 
insufficiency (eGFR <30 ml/min), data for the use of 
simeprevir, ledipasvir, sofosbuvir, and other direct 
acting antivirals are emerging. Although the use of 
sofosbuvir is currently not recommended in patients 
with eGFR <30 ml/min, safety and efficacy of full dose 
sofosbuvir regimen was recently demonstrated in this 
population (28).  
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The 3D regimen, comprising of paritaprevir/ 
ritonavir/ ombitasvir + dasabuvir as well as the NS5A 
inhibitor daclatasvir, has been safely administered in 
patients with severe renal insufficiency (GFR <30 
ml/min) due to the predominant biliary elimination of 
these drugs (29). The combination of grazoprevir plus 
elbasvir, licensed in 2016, has shown a good safety 
profile in patients with serious renal impairment in a 
dedicated trial. 
A particularity of this case was the large number of 
signs and symptoms indicating increased activity of the 
autoimmune disease. The prevalence of renal 
involvement in the second type of cryoglobulinemia is 
variable, from 10 to 60% (4, 6, 30, 31), most often 
occurring between the 5th and 6th decades of life, with 
a moderate female predominance (32, 33). These 
parameters describe our case, as the patient was female 
and 59 years old. Although the renal and systemic 
manifestations may appear simultaneously, most often 
episodes of extra-renal symptomatology with 
spontaneous remission are present before the installation 
of the renal manifestations (6, 32, 33). The case 
described herein belongs to the classical triad described 
by Meltzer and Franklin: fatigability, purpura, and 
polyarthralgias, as noted in about one third of the cases 
(30, 34, 35). While establishing the diagnosis, we noted 
a moderate affectation of the nervous system, with faint 
acroparesthesias. Other manifestations such as 
pulmonary affectation or CNS issues are generally rare 
and were excluded in our case. A cardiovascular 
investigation was carried out, and although the 
cryoglobulinemic vasculitis can determine the 
development of pericarditis, valvular pathology, 
myocarditis, and congestive cardiac (6, 32), only a 
primary arterial hypertension of the second degree was 
found, which was therapeutically controlled.  
In our case, the patient is a C virus carrier, with 
active replication for several years, being subjected to 
several investigations for the evaluation of hepatic 
function. The prognosis of the hepatic disease is based 
on the degree of fibrosis, a proper, complete, and early 
evaluation being essential. Although the hepatic biopsy 
remains the “gold standard,” a series of noninvasive 
techniques concerned with the evaluation of the degree 
of fibrosis, including RTE, have recently been recently. 
This contemporary and noninvasive method enables 
evaluation of the differences of hardness between 
affected and healthy tissues, with applicability that 
varies from the differentiation of malign tumors from 
benign ones via the evaluation of the degree of elasticity 
specific to a tumoral tissue, up to the evaluation of the 
degree of hepatic fibrosis (36). 
The close relation between the infection with HCV 
and the cryoglobulinemia is demonstrated after 
treatment with Interferon for 12 months in 2015 when 
an increase in the seric values of RF-IgM, viremy, and 
creatinine were noticed, with an amelioration of the 
renal function, reaching a eGFR of 13 mL/min/1.73m2 
before the initiation of the treatment, a rate of 22 
mL/min/1.73m2, at the end of the 12 months; the 
cutaneous symptomatology entered remission. The 
patient was, however, a non-responder to the therapy 
with interferon, which led to another remission at the 
end of the treatment, with the recurrence the vasculitic 
symptomatology and the increase in the values of the 
nitrogen retention.  
The status of being a non-responder exposed the 
patient to both the progressive deterioration of the 
hepatic function, with the gradual installation of 
cirrhosis and its complications, and the development of 
a hepatocellular carcinoma, which led to the use of 
periodical RTE, as this technique can be applied in 
either case. By the LFI, the degree of hepatic fibrosis 
and potential tumorous formations can be determined. 
 
Conclusions 
This case study reveals the close connection 
between the infection with the HCV and the 
cryoglobulinemic vasculitis with cutaneous, renal, and 
neurologic injury, its particularity being represented by 
both the existence from the outset of the vasculitic 
disease of a large number of signs and symptoms 
specific to vasculitis, and the current predialitic stage of 
the patient, due to the deterioration of the renal function 
during the last years. This pattern is not characteristic of 
type II cryoglobulinemia, which in most cases does not 
progress towards dialysis, although the affected area is 
moderate since the establishment of the diagnosis (6, 35, 
36).  
Taking into account the failure of the therapy with 
interferon and the progressive accentuation of all the 
complications, close monitoring of the clinical and 
paraclinical state is necessary at periodic time intervals. 
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